Remdesivir has little effect on Covid19 mortality WHO study

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=GQOGYi-yuzk

A new study by the World Health Organization said the antiviral drug remdesivir has little to no effect on mortality for those hospitalized with Covid-19. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi • A study coordinated by the World Health Organization has indicated that remdesivir, along with three other potential drug treatments for the coronavirus, has “little or no effect” on death rates among hospitalized patients. • The interim results from the WHO’s Solidarity Therapeutics Trial, said to be the world’s largest randomized control trial of coronavirus treatments, were published Thursday. • The results indicated that the remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon drug treatment regimens “appeared to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among hospitalized patients.” • Remdesivir is one of the drugs given to U.S. President Donald Trump after he tested positive for the coronavirus two weeks ago. • The randomized study by the WHO was conducted in 405 hospitals across 30 countries on 11,266 patients, with 2750 given remdesivir. • “No study drug definitely reduced mortality (in unventilated patients or any other subgroup of entry characteristics), initiation of ventilation or hospitalisation duration,” the authors of the study wrote. • Randomized controlled trials are considered the “gold standard” of clinical studies because they more effectively eliminate bias. However, the WHO study has not yet been peer reviewed, which means it has not been independently evaluated by other experts. • The WHO’s findings come a week after drugmaker Gilead Sciences published the final data on its own large-scale trial of remdesivir. Gilead originally developed remdesivir to treat the Ebola virus. • » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision • » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC • » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic • Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. • The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-n... • • Connect with CNBC News Online • Get the latest news: http://www.cnbc.com/ • Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC • Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC • Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC • Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC • • https://www.cnbc.com/select/best-cred... • #CNBC • #CNBCTV

#############################

New on site